Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Other Operating Expenses (2016 - 2026)

Integra Lifesciences Holdings' Other Operating Expenses history spans 16 years, with the latest figure at $217.8 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 10.41% to $217.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 77.38% increase, with the full-year FY2025 number at $1.3 billion, changed N/A from a year prior.
  • Other Operating Expenses hit $217.8 million in Q4 2025 for Integra Lifesciences Holdings, up from $198.8 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for IART hit a ceiling of $721.4 million in Q2 2025 and a floor of -$679000.0 in Q2 2021.
  • Historically, Other Operating Expenses has averaged $163.4 million across 5 years, with a median of $177.3 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: surged 380.0% in 2022 and later increased 7.83% in 2025.
  • Tracing IART's Other Operating Expenses over 5 years: stood at -$169000.0 in 2021, then skyrocketed by 481.07% to $644000.0 in 2022, then soared by 27425.93% to $177.3 million in 2023, then rose by 11.29% to $197.3 million in 2024, then increased by 10.41% to $217.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for IART at $217.8 million in Q4 2025, $198.8 million in Q3 2025, and $721.4 million in Q2 2025.